News

Cellectis and Lonza announced that the companies have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates…
Read More...

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft Corp. as its strategic AI and data-science partner for…
Read More...

Servier announced the acquisition of PIXUVRI from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.…
Read More...

Chimerix announces an exclusive global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop,…
Read More...

Ocugen, Inc. a clinical stage biopharmaceutical company focused on innovative therapies that address rare and underserved eye diseases, has entered into a strategic partnership with…
Read More...

Moberg Pharma AB has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd for development, registration and commercialization of MOB-015 in Japan. Under the…
Read More...

Swedish Orphan Biovitrum AB (publ) (Sobi) announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. by means of a tender offer. The consideration consists of an upfront…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with…
Read More...

Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced the acquisition of Nalpropion Pharmaceuticals. As a result of…
Read More...

Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the…
Read More...

Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been…
Read More...

Moderna, Inc., a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...

SpringWorks Therapeutics announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the…
Read More...

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready…
Read More...

Achillion Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination…
Read More...

IMMUNOPRECISE ANTIBODIES, an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, its wholly-owned subsidiary, has entered into an LOI…
Read More...

Zealand Pharma A/S announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes. Dasiglucagon is a potential first-in-class soluble…
Read More...

Aldeyra Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy…
Read More...

Pfizer Inc. and Flatiron Health announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer’s development of innovative targeted…
Read More...

The U.S. Food and Drug Administration announced the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in…
Read More...